ClinicalTrials.gg
CompletedNCT06851871Updated Apr 29, 2025

A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

A Phase 1 interventional study of Deucravacitinib and Famotidine in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the bioequivalence between immediate release tablets and minitablets of Deucravacitinib (BMS-986165), and the effect of food and pH on the drug levels of the minitablets in healthy adults.

02

Conditions studied

  • Healthy Participants

Keywords

  • Bioequivalence
  • Food Effect
  • pH Effect
  • Healthy Volunteers
  • Deucravacitinib
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy as determined by no deviation from normal in medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory determinations in the opinion of the investigator.
  • Participants must be willing and able to complete all study-specific procedures and visits.
  • Participants must have a of 18.0 kg/m2 through 32.0 kg/m2, inclusive, and total body weight ≥ 50 kg (110 lb).

Exclusion criteria

Exclusion Criteria

  • Participants must not have any significant acute or chronic medical illness that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of/or acute liver disease in the opinion of the Investigator.
  • Participants must not have evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, 12-lead , or clinical laboratory determinations beyond what is consistent with the population reference ranges in the opinion of the investigator.
  • Participants must not have any history of severe reaction to a drug (eg, anaphylactic, anaphylactoid, Stevens-Johnson, angioedematous), or adverse or allergic/ reaction to multiple drugs.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    BMS-986165 Formulation 1

    Drug: Deucravacitinib

  • Experimental
    BMS-986165 Formulation 2

    Drug: Deucravacitinib

  • Experimental
    BMS-986165 Formulation 2 + Fed

    Drug: Deucravacitinib

  • Experimental
    BMS-986165 Formulation 2 + Famotidine

    Drug: Deucravacitinib · Drug: Famotidine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to day 20

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to day 20

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to day 20

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to day 44

  2. Incidence of serious adverse events (SAEs)

    Time frame: Up to day 44

  3. Incidence of AEs leading to discontinuation

    Time frame: Up to day 44

  4. Number of participants with a clinically significant change from baseline in vital signs

    Time frame: Up to day 21

  5. Number of participants with a change from baseline in 12-lead ECG results

    Time frame: Up to day 21

  6. Number of participants with physical examination abnormalities

    A physical examination includes the assessment of the following: head, eyes, ears, nose, and throat (HEENT), cardiovascular (including peripheral vascular), lungs, abdomen, dermatological, and a general neurological examination

    Time frame: Up to day 21

  7. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to day 20

  8. Apparent terminal plasma half-life (T-HALF)

    Time frame: Up to day 20

  9. Apparent total body clearance (CLT/F)

    Time frame: Up to day 20

07

Study locations

1 site
  • Local Institution - 0001
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Apr 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Feb 28, 2025
StartActual
Jan 23, 2025
Primary completionActual
Apr 4, 2025
CompletionActual
Apr 4, 2025
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06851871
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Jan 23, 2025
Primary completion
Apr 4, 2025
Completion
Apr 4, 2025
Last update
Apr 29, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion